Core Viewpoint - The Chinese beauty industry is experiencing a significant shift as domestic brands rush to list on the Hong Kong Stock Exchange, driven by a near closure of IPO opportunities in the A-share market. This trend is not merely a celebration but signals a harsh beginning of industry differentiation and value reassessment [1][5]. Group 1: Market Dynamics - The successful listings of brands like Lin Qingxuan and the planned secondary listing of Proya highlight Hong Kong as a new haven for domestic beauty brands [1]. - The high price-to-earnings (PE) ratio of over 30 for Mao Geping is misleading, as it reflects a unique business model rather than a general trend in the domestic beauty sector [4]. - The market is expected to shift focus from the narrative of domestic brand growth to a stringent evaluation of business fundamentals [5]. Group 2: Brand Performance and Strategy - HBN and Banmu Huatian rely on traditional consumer goods models, heavily investing in marketing to drive growth, contrasting with Mao Geping's unique model that minimizes external marketing dependency [6][8]. - HBN's financials show a significant profit growth rate of 232.5% and 190.3% for 2024 and the first nine months of 2025, respectively, despite a marketing expense ratio of 57.6% [8]. - The key for HBN post-listing is to demonstrate that it can achieve higher brand premiums and customer lifetime value with the same marketing investment compared to competitors [10]. Group 3: Liquidity and Market Pressure - The liquidity risk in the Hong Kong market is severe, with top-tier companies absorbing most capital, leaving mid-tier brands vulnerable to becoming illiquid [12]. - The pressure of performance guarantees for many domestic brands in 2024-2025 may lead to unsustainable practices, risking significant stock price drops if growth slows post-2026 [13]. Group 4: Competitive Landscape - The competition in the beauty industry is evolving from ingredient concentration to structural competition, with brands needing to lower marketing costs while maintaining revenue [15]. - Unique raw materials are becoming essential for brand differentiation and valuation in the market, as seen with successful brands like Juzhibio and Lin Qingxuan [18]. - The necessity for international expansion is increasing, as domestic market growth is plateauing, making overseas markets critical for future success [20]. Group 5: Future Outlook - The Hong Kong market is becoming increasingly discerning, seeking brands that can demonstrate efficiency and long-term viability rather than just rapid growth [22][23]. - Brands that can effectively manage their desires, respect market realities, and commit to long-term strategies will be better positioned for success in the evolving landscape [23].

Core Insights - The company Lin Qingxuan, despite a high gross margin of 82.5% on its Camellia oil priced at 749 yuan, faces serious issues including false advertising, hollow R&D, and a halved valuation [2][3] - Regulatory scrutiny has intensified, with the Beijing Chaoyang District Market Supervision Bureau imposing fines for misleading claims about product efficacy [2][8] - The company is under pressure to go public due to multiple agreements with investors, leading to significant share sell-offs by founders and early investors [3][6][7] Group 1: Financial Performance and Valuation - Lin Qingxuan's valuation peaked at 3.175 billion yuan during its B round financing in 2021 but plummeted to 1.559 billion yuan by August 2024 [4][6] - The company has seen significant cash-outs by its founder and early investors, totaling 226 million yuan from August 2024 to May 2025 [3][6] - The financial data reveals a troubling reliance on a few core products, with nearly 40% of revenue coming from a single item [3][15] Group 2: Marketing vs. R&D - The marketing expenditure for 2024 was 365 million yuan, while R&D investment was only 30.4 million yuan, indicating a 12-fold disparity [10][11] - Over the years, the company has spent 760 million yuan on marketing but only 71.2 million yuan on R&D, which is less than 3% of total revenue [10][11] - The workforce is heavily skewed towards sales and marketing, with 85.2% of employees in these roles and only 64 in R&D [11] Group 3: Product Dependency and Market Challenges - The Camellia oil product accounted for 37% of total revenue in 2024, highlighting a lack of diversification in the product lineup [15] - The company has struggled to establish a foothold in lower-tier markets, with sales in these areas only reaching 60% of those in first-tier cities [15] - The franchise model has faced setbacks, with the number of franchise stores decreasing from 35 to 32, and average revenue per store significantly lower than that of direct-operated stores [15] Group 4: Regulatory and Market Pressures - The company has a history of regulatory violations, including a recent fine for false advertising regarding its anti-aging claims [8][9] - The upcoming deadline for a public listing in December 2026 poses a significant risk, as failure to meet this could result in substantial financial liabilities for the founder [19][20] - New regulations on cosmetic efficacy claims are tightening, which could further impact the company's marketing strategies [19][20]